[go: up one dir, main page]

PE20020101A1 - Metodo para la preparacion de composiciones - Google Patents

Metodo para la preparacion de composiciones

Info

Publication number
PE20020101A1
PE20020101A1 PE2001000603A PE2001000603A PE20020101A1 PE 20020101 A1 PE20020101 A1 PE 20020101A1 PE 2001000603 A PE2001000603 A PE 2001000603A PE 2001000603 A PE2001000603 A PE 2001000603A PE 20020101 A1 PE20020101 A1 PE 20020101A1
Authority
PE
Peru
Prior art keywords
methyl
sodium
dispersion
homogeneous
compositions
Prior art date
Application number
PE2001000603A
Other languages
English (en)
Inventor
Marco Schroeder
Patrick Busson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20020101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020101A1 publication Critical patent/PE20020101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN METODO PARA PREPARAR COMPOSICIONES QUE COMPRENDE: a)PREPARAR UNA SOLUCION O DISPERSION HOMOGENEA DE UN LIQUIDO Y UN COMPUESTO TAL COMO OSELTAMIVIR o (5-[7-[2-(5-METIL-2-FENIL-OXAZOL-4-IL)-ETOXI]-BENZOTIOFEN-4-METIL]-2,4-TIAZOLIDINDIONA o UN INHIBIDOR DE LIPASAS COMO ORLISTAT; EXCIPIENTES QUE CONTIENEN UN MATERIAL DE RECUBRIMIENTO O FORMADOR DE UNA PASTA VITREA COMO POLIOL (MALTODEXTRINA, TREHALOSA, MALTITOL, GLUCOSA, ENTRE OTROS), GOMA O POLIMERO (POLIENTIELENGLICOL, ALMIDON, CELULOSA, POVIDONA, ENTRE OTROS), TENSIOACTIVO (LAURILSULFATO DE SODIO, DOCUSATO DE SODIO, CASEINATO DE SODIO, SALES DE ACIDO GRASO, ENTRE OTROS); b)EXPANSION DE LA SOLUCION O DISPERSION HOMOGENEA QUE DESARROLLA UN VOLUMEN Y SUPERFICIE MAYORES MEDIANTE UN CAMBIO (DISMINUCION) DE LA PRESION ENTRE 30 Y 150 TORR SIN LLEGAR A LA EBULLICION; c)SECADO O ENFRIADO. LA COMPOSICION SE CARACTERIZA POR TENER UN NIVEL DE SOLVENTE RESIDUAL ENTRE 0,1%p/p Y 10%p/p; DENSIDAD APARENTE (POR VERTIDO) ENTRE 0,1g/cm3 Y 0,9g/cm3; TAMANO DE PARTICULAS ENTRE 50µm Y 600µm
PE2001000603A 2000-06-27 2001-06-21 Metodo para la preparacion de composiciones PE20020101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00113535 2000-06-27

Publications (1)

Publication Number Publication Date
PE20020101A1 true PE20020101A1 (es) 2002-02-12

Family

ID=8169074

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000603A PE20020101A1 (es) 2000-06-27 2001-06-21 Metodo para la preparacion de composiciones

Country Status (37)

Country Link
US (3) US6534087B2 (es)
EP (1) EP1296656B1 (es)
JP (2) JP4149803B2 (es)
KR (1) KR100557845B1 (es)
CN (1) CN1236764C (es)
AR (1) AR029278A1 (es)
AT (1) ATE334662T1 (es)
AU (2) AU8184601A (es)
BR (1) BRPI0112014B1 (es)
CA (1) CA2411153C (es)
CY (1) CY1105714T1 (es)
CZ (1) CZ301813B6 (es)
DE (1) DE60121953T2 (es)
DK (1) DK1296656T3 (es)
EC (1) ECSP024401A (es)
EG (1) EG24141A (es)
ES (1) ES2269441T3 (es)
HR (1) HRP20021009B1 (es)
HU (1) HU229550B1 (es)
IL (2) IL153282A0 (es)
JO (1) JO2247B1 (es)
MA (1) MA26922A1 (es)
ME (1) MEP90608A (es)
MX (1) MXPA02012583A (es)
MY (1) MY129798A (es)
NO (1) NO332181B1 (es)
NZ (1) NZ523024A (es)
PE (1) PE20020101A1 (es)
PL (1) PL203804B1 (es)
PT (1) PT1296656E (es)
RU (1) RU2244542C2 (es)
SI (1) SI1296656T1 (es)
TW (1) TWI278325B (es)
UY (1) UY26799A1 (es)
WO (1) WO2002000201A2 (es)
YU (1) YU96602A (es)
ZA (1) ZA200209649B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
HU229550B1 (en) * 2000-06-27 2014-01-28 Hoffmann La Roche Method for preparing compositions
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
MY135783A (en) * 2001-09-07 2008-06-30 Meiji Dairies Corp Nutritional composition for controlling blood sugar level
AU2003222814B2 (en) * 2002-04-26 2006-08-24 Cheplapharm Arzneimittel Gmbh Pharmaceutical composition comprising a lipase inhibitor and glucomannan
KR100517072B1 (ko) * 2002-11-25 2005-09-26 주식회사 태평양 폴리올/고분자 마이크로캡슐 및 이를 이용한 효소 안정화방법
US9174176B2 (en) * 2003-01-09 2015-11-03 Disperse Systems, Inc. Ultrasonic dispersion apparatus, system, and method
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
US8030362B2 (en) 2003-12-12 2011-10-04 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
WO2005109990A2 (en) * 2004-04-06 2005-11-24 Rpg Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
WO2006030784A1 (ja) * 2004-09-15 2006-03-23 Banyu Pharmaceutical Co., Ltd. サンプリング方法、サンプリング装置、ｌｏｇＤ測定方法及びｌｏｇＤ測定システム
EP1837032A4 (en) * 2004-12-31 2009-06-10 Mikhail Yurievich Gotovsky MAGNETIC RESONANCE PREPARATIONS AND DEVICE FOR INDIVIDUALLY SELECTING SUCH PREPARATIONS TO INCREASE THE ACTIVITY OF AN ORGANISM UNDER CURRENT ENVIRONMENTAL CONDITIONS
US20060198856A1 (en) * 2005-03-01 2006-09-07 Keith Whitehead Ibuprofen suspension stabilized with docusate sodium
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US7984717B2 (en) * 2005-04-29 2011-07-26 Medtronic, Inc. Devices for augmentation of lumen walls
WO2006138431A2 (en) * 2005-06-16 2006-12-28 Eastman Chemical Company Methods and pharmaceutical formulations for increasing bioavailability
WO2006136196A1 (en) * 2005-06-21 2006-12-28 V. Mane Fils Gellan seamless breakable capsule and process for manufacturing thereof
WO2006136197A1 (en) 2005-06-21 2006-12-28 V. Mane Fils Smoking device incorporating a breakable capsule, breakable capsule and process for manufacturing said capsule
US20070048364A1 (en) * 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
US10010494B2 (en) 2005-10-19 2018-07-03 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
ES2470340T3 (es) 2005-12-28 2014-06-23 Advanced Bionutrition Corporation Vehículo de administración para bacterias probi�ticas que comprende una matriz seca de polisac�ridos, sac�ridos y polioles en forma vítrea
FR2895908B1 (fr) * 2006-01-12 2008-03-28 France Etat Procede de fabrication d'une forme pharmaceutique de phosphate d'oseltamivir
ZA200806356B (en) 2006-02-20 2009-11-25 Chugai Pharmaceutical Co Ltd Pharmaceutical composition comprising oseltamivir phosphate
EP2002201A2 (en) 2006-03-16 2008-12-17 Duke University Methods, systems, and computer program products for performing real-time quadrature projection based fourier domain optical coherence tomography
CN1820744B (zh) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
KR100812824B1 (ko) 2006-09-27 2008-03-12 주식회사 제닉 키토산과 폴리에틸렌글리콜을 이용한 생체친화성 저독성필름
CA2673120C (en) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation A dry food product containing live probiotic
AU2008254748A1 (en) * 2007-05-18 2008-11-27 Tti Ellebeau, Inc. Transdermal delivery devices assuring an improved release of an active principle through a biological interface
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
ES2908047T3 (es) 2009-03-27 2022-04-27 Intervet Int Bv Vacunas en micropartículas para la vacunación oral o nasal y el refuerzo de animales incluidos los peces
CN102459568A (zh) 2009-05-26 2012-05-16 先进生物营养公司 包含生物活性微生物和/或生物活性材料的稳定干粉组合物及其制造方法
EP2482802A4 (en) * 2009-09-29 2013-08-07 Michael Burnet NEW PESTICIDE FORMULATIONS
KR100940745B1 (ko) * 2009-10-15 2010-02-04 광동제약 주식회사 오를리스타트 및 아타풀지트 함유 복합제의 코팅펠렛 및 이를 이용한 제제
PH12012501410A1 (en) 2010-01-28 2012-10-22 Advanced Bionutrition Corp Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101021030B1 (ko) * 2010-03-25 2011-03-09 엘지이노텍 주식회사 형광체 코팅방법, 발광장치 제조방법 및 코팅된 형광체
US9404076B2 (en) * 2010-04-07 2016-08-02 Mitsubishi Gas Chemical Company, Inc. S-adenosyl-L-methionine-containing dry yeast composition with excellent storage stability and process for producing same
PH12013500272B1 (en) 2010-08-13 2019-07-03 Advanced Bionutrition Corp Dry storage stabilizing composition for biological materials
AU2011320159B2 (en) 2010-10-29 2016-12-22 Western University Of Health Sciences Ternary mixture formulations
AU2012229476B2 (en) 2011-03-01 2016-02-25 The Procter & Gamble Company Porous disintegratable solid substrate for personal health care applications
KR102062645B1 (ko) 2012-03-23 2020-01-06 어드밴스드 바이오뉴트리션 코프. 생물학적 물질용 안정화 조성물
CN103222964B (zh) * 2013-01-29 2014-10-08 青岛大学 一种奥利司他口服制剂及其制备方法
GB2524496A (en) * 2014-03-24 2015-09-30 British Airways Plc Dynamic tracking and control of passenger travel progress
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
TW201713775A (zh) 2015-06-25 2017-04-16 亞斯科生物科學公司 用於自複雜的異源群集中分析微生物品系、預測及識別其機能性關係及交互作用，且依據前述選擇並合成微生物系集之方法、裝置及系統
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
DK3328215T3 (da) 2015-07-29 2021-09-13 Advanced Bionutrition Corp Stabilt tørre probiotiske sammensætninger til særlige kostanvendelser
JP6778051B2 (ja) * 2016-08-18 2020-10-28 沢井製薬株式会社 オセルタミビルリン酸塩含有医薬組成物
US12018313B2 (en) 2016-12-28 2024-06-25 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles
EP3562954A1 (en) 2016-12-28 2019-11-06 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
WO2019069108A1 (en) * 2017-10-04 2019-04-11 Debreceni Egyetem SOLID GALENIC FORM, MOLDED, GASTRIC RETENTION AND EXTENDED RELEASE AND METHOD OF PREPARING THE SAME

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
US4489438A (en) * 1982-02-01 1984-12-18 National Data Corporation Audio response system
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
JP3069458B2 (ja) 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
US5560921A (en) 1992-06-01 1996-10-01 The Procter & Gamble Company Chewable decongestant compositions
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
NZ262562A (en) * 1993-02-23 1996-04-26 Warner Lambert Co Preparation of solvent free pharmaceutical compositions
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5536264A (en) * 1993-10-22 1996-07-16 The Procter & Gamble Company Absorbent composites comprising a porous macrostructure of absorbent gelling particles and a substrate
US5523106A (en) * 1994-02-03 1996-06-04 Nabisco, Inc. Juice-based expanded snacks and process for preparing them
CA2546660C (en) 1995-02-27 2009-08-11 Gilead Sciences Inc. Selective inhibitors of viral or bacterial neuraminidase
HU228450B1 (en) 1995-02-27 2013-03-28 Gilead Sciences Inc Novel selective inhibitors of viral or bacterial neuraminidases
WO1996040077A2 (en) * 1995-06-07 1996-12-19 Quadrant Holdings Cambridge Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
US5763483A (en) * 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
PT893992E (pt) * 1996-04-16 2004-06-30 Novartis Consumer Health Sa Formas de dosagem oral de desintegracao rapida
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
WO1998016204A1 (en) * 1996-10-14 1998-04-23 F. Hoffmann-La Roche Ag Process for the manufacture of a pulverous preparation
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
JPH11137208A (ja) 1997-11-14 1999-05-25 Nikken Chem Co Ltd 口腔内速溶性固形物及びその製造方法
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
KR20010042566A (ko) * 1998-04-09 2001-05-25 프리돌린 클라우스너, 롤란드 비. 보레르 압축된 기체 및 계면활성제중에 용해시킴으로써, 크기가마이크론 이하인 입자를 제조하는 방법
WO2000009122A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
DE69916288T2 (de) 1998-08-14 2005-03-24 F. Hoffmann-La Roche Ag Lipasehemmer und chitosan enthaltende arzneimittel
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
GB9904629D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Oral drug delivery system
FR2791569B1 (fr) * 1999-03-31 2003-05-09 Pf Medicament Composition ou structure microporeuse expansee isotrope a dissolution rapide a usage pharmaceutique, veterinaire, dietetique, alimentaire ou cosmetique et son procede d'obtention
HU229550B1 (en) * 2000-06-27 2014-01-28 Hoffmann La Roche Method for preparing compositions

Also Published As

Publication number Publication date
CZ2003212A3 (cs) 2003-06-18
CA2411153A1 (en) 2002-01-03
US6534087B2 (en) 2003-03-18
PL203804B1 (pl) 2009-11-30
SI1296656T1 (sl) 2006-12-31
HK1058314A1 (en) 2004-05-14
CZ301813B6 (cs) 2010-06-30
HU229550B1 (en) 2014-01-28
CA2411153C (en) 2007-01-30
DK1296656T3 (da) 2006-11-27
RU2244542C2 (ru) 2005-01-20
NO332181B1 (no) 2012-07-16
JP4149803B2 (ja) 2008-09-17
NO20026197D0 (no) 2002-12-23
MXPA02012583A (es) 2003-04-10
ME00672B (me) 2011-12-20
IL153282A (en) 2008-03-20
NO20026197L (no) 2002-12-23
AR029278A1 (es) 2003-06-18
ATE334662T1 (de) 2006-08-15
CY1105714T1 (el) 2010-12-22
ECSP024401A (es) 2003-02-06
HRP20021009B1 (hr) 2011-07-31
HRP20021009A2 (en) 2004-02-29
KR20030023880A (ko) 2003-03-20
US20020018812A1 (en) 2002-02-14
TWI278325B (en) 2007-04-11
US20060134205A1 (en) 2006-06-22
BRPI0112014B1 (pt) 2016-09-13
WO2002000201A3 (en) 2002-04-18
AU8184601A (en) 2002-01-08
CN1438880A (zh) 2003-08-27
YU96602A (sh) 2005-03-15
DE60121953D1 (de) 2006-09-14
NZ523024A (en) 2004-08-27
PL365803A1 (en) 2005-01-10
HUP0302060A2 (hu) 2003-09-29
ZA200209649B (en) 2004-03-10
CN1236764C (zh) 2006-01-18
DE60121953T2 (de) 2007-03-08
JP2004501184A (ja) 2004-01-15
WO2002000201A2 (en) 2002-01-03
EG24141A (en) 2008-08-06
IL153282A0 (en) 2003-07-06
PT1296656E (pt) 2006-12-29
JP2007302683A (ja) 2007-11-22
ES2269441T3 (es) 2007-04-01
MY129798A (en) 2007-04-30
MEP90608A (bs) 2011-12-20
UY26799A1 (es) 2001-12-28
AU2001281846B2 (en) 2006-04-27
EP1296656A2 (en) 2003-04-02
BR0112014A (pt) 2003-05-13
KR100557845B1 (ko) 2006-03-10
MA26922A1 (fr) 2004-12-20
JO2247B1 (en) 2004-10-07
EP1296656B1 (en) 2006-08-02
US20030039614A1 (en) 2003-02-27
HUP0302060A3 (en) 2006-07-28
US7074431B2 (en) 2006-07-11

Similar Documents

Publication Publication Date Title
PE20020101A1 (es) Metodo para la preparacion de composiciones
AU5523599A (en) Method for preparing novel fenofibrate galenic formulations, galenic formulations obtained and applications
PE63299A1 (es) Una dispersion acuosa de un solido particulado que tiene una superficie externa hidrofobica y peliculas producidas por la misma
ES2154650T3 (es) Composicion que comprende una formulacion con factor de coagulacion viii, procedimiento para su preparacion y uso de un tensioactivo como estabilizador.
SE8404804D0 (sv) Forfarande for framstellning av farmaceutiska kompositioner med fordrojd frigoring och med en hog halt aktiv bestandsdel
BR0002558A (pt) Processo para preparar uma composição de copolìmero intrinsecamente condutor, composição, e, processo para uso de um copolìmero intrinsecamente condutor
CO5040140A1 (es) Composiciones detergentes para superficies duras que comp- prenden un polimero hidrofilo a nivel muy bajo que atenua el esfuerzo cortante
AR014583A1 (es) Composicion de agente tensioactivo capaz de estructurar una composicion liquida no acuosa y particula estructurante que la comprende
MX165822B (es) Detergente mas suavizador con ingredientes de imidazolina
FR2443502A1 (fr) Comprime detergent comportant un enrobage de sel hydrate et procede de preparation du comprime
JPS529006A (en) Liquid bleaching detergent composition
WO1997015385A1 (fr) Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles
CA2426764A1 (en) Nateglinide-containing hydrophilic pharmaceutical preparation
ES2146064T3 (es) Metodo de producir un producto repelente del agua, y producto y metodo para impermeabilizar una superficie de un material de construccion.
KR20130015469A (ko) 개선된 제형 안정도를 갖는 워시오프 화장료 조성물
ES534215A0 (es) Una composicion para enjuagar el cabello
BR9812756A (pt) Processo para produzir uma composição detergente granular de densidade elevada contendo tensoativos ramificados de cadeias médias
BE884848A (fr) Sel mixte d'acide valproique utile notamment pour le traitement de l'epilepsie, presentant des caracteristiques tres superieures de stabilite
ES2136255T3 (es) Alcohol polivinilico extrusionado, que contiene un perfume y su utilizacion.
CU22610A3 (es) Composición sólida
AU1867983A (en) Substituted benzenesulfonic esters
BR9914919A (pt) Composição lìquida aquosa
JPS55139313A (en) Gel cream composition comprising higher fatty acid ethanol amide, and drug containing it
JPS5735509A (en) Analgesic and antiphlogistic cream
JPS55115859A (en) Carboxylic ester, its preparation, insecticide and acaricide with low toxicity to fish comprising it as active constituent

Legal Events

Date Code Title Description
FG Grant, registration